Entera Bio (FRA:5DT) Dividend Payout Ratio : 0.00 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Entera Bio Dividend Payout Ratio?

Entera Bio's dividend payout ratio for the months ended in Mar. 2024 was 0.00.

The historical rank and industry rank for Entera Bio's Dividend Payout Ratio or its related term are showing as below:

FRA:5DT's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.44
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-04), the Dividend Yield % of Entera Bio is 0.00%.

Entera Bio's Dividends per Share for the months ended in Mar. 2024 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Entera Bio Dividend Payout Ratio Historical Data

The historical data trend for Entera Bio's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entera Bio Dividend Payout Ratio Chart

Entera Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

Entera Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Entera Bio's Dividend Payout Ratio

For the Biotechnology subindustry, Entera Bio's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entera Bio's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Entera Bio's Dividend Payout Ratio falls into.

Entera Bio Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Entera Bio's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-0.284
	=	N/A

Entera Bio's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-0.046
	=	N/A

Entera Bio (FRA:5DT) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Entera Bio Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Entera Bio's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Entera Bio (FRA:5DT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (FRA:5DT) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

ENTX:USA

Address

Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002

Website

https://www.enterabio.com

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Entera Bio (FRA:5DT) Headlines

No Headlines